Drug lookup | Fillwise

BIMATOPROST

All products: not a benefit

Other products in the same Health Canada class (S01E, S01EE) — coverage varies; not interchangeable

Latanoprost (Xalatan): limited Use 171, 172, 387
Latanoprostene bunod (Vyzulta): limited Use 171, 172, 387
Travoprost (Izba): limited Use 171, 172, 387
Acetazolamide (Acetazolamide): general benefit, Not a benefit
Betaxolol (Betoptic S): general benefit
Levobunolol (Betagan): general benefit

11 more in the class list below

Lumigan · DIN 02245860 · 0.03% · Oph Sol

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-11-17 — choose a marketed DIN from the same-category list.Discontinued 2023-11-17 · checked 2026-09-19

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-11-17 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2023-11-17 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 171, 172, 387

Reason for Use code 171 As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 172 As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 387 For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite

1 brand, same coverage

Lumigan · DIN 02245860 Manufacturer: Allergan Inc.; listing date 2004-04-06 Health Canada: Cancelled post market since 2023-11-17 · brand LUMIGAN · ATC S01EE03 BIMATOPROST · form Solution · route Ophthalmic · ingredients BIMATOPROST 0.03 % · company Allergan inc · schedule Prescription

Check this DIN again · Health Canada product record

Lumigan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69977 · Verify on the e-Formulary ↗ (DIN 02245860)

Source record

DIN 02245860: Lumigan Raw flags: notABenefit=Y, sec3=Y Item: 523600104; group id 613; item number 1577; lccId 00152; manufacturer id ALL Source form: Oph Sol; strength: 0.03% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245860 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69977

Interchangeable products

Vistitan · DIN 02429063 · $9.1936

Shortage status: not checked (no credentials)

Health Canada lists this DIN as Cancelled post market since 2023-11-17 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE 52:36 Other Eye, Ear, Nose and Throat Agents

LATANOPROST

· 9 products · Limited Use, codes 171, 172, 387 · strengths: 0.005% · Oph Sol-2.5mL Pk

LATANOPROSTENE BUNOD

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 0.024%w/v · Oph Sol

TRAVOPROST

· 4 products · Limited Use, codes 171, 172, 387 · strengths: 0.003%, 0.004% · Oph Sol (with Preservative), Oph Sol-5mL Pk

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

TIMOLOL MALEATE

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol

BRIMONIDINE

· 7 products · Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol

BRIMONIDINE TARTRATE & TIMOLOL MALEATE

· 3 products · Limited Use, codes 310, 393 · strengths: 0.2% & 0.5% · Oph Sol-10mL Pk

BRINZOLAMIDE

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 1% · Oph Susp

BRINZOLAMIDE & BRIMONIDINE TARTRATE

· 1 products · Limited Use, codes 466, 393 · strengths: 1.0% & 0.2% · Oph Susp-10mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:36 and 20 more

Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.

Other drugs whose Health Canada label lists a similar indication: elevated intraocular pressure

From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. BRINZOLAMIDE · Limited Use, codes 171, 172, 387 • the treatment of elevated intraocular pressure (IOP) in adult patients with ocular hypertension or open-angle glaucoma. PM: https://pdf.hres.ca/dpd_pm/00069562.PDF; date OCT 23, 1998; DIN 02238873; fetched 2026-09-10 Product monograph TIMOLOL MALEATE · Listed, not a benefit (5), General benefit (11)  the reduction of elevated intraocular pressure PM: https://pdf.hres.ca/dpd_pm/00067983.PDF; date OCT 28, 2016; DIN 00451207; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26

What the Health Canada label says it is for

INDICATIONS AND CLINICAL USE Vistitan (bimatoprost ophthalmic solution 0.03% w/v) is indicated for:  the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension Geriatrics (> 65 years of age): No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients. Use as for adult patients. Pediatrics (<18 years of age): Not recommended for pediatric use. Safety and effectiveness in pediatric patients have not been established. https://pdf.hres.ca/dpd_pm/00049647.PDF PM date: January 28, 2019 Source product: VISTITAN; DIN 02429063; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Lumigan: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026